Table 1.
Baseline or 0’ (fasting) | 10’ | 15’ | 20’ | 30’ | 45’ | 60’ | 120’ | 180’ | Next day | ||
Primary endpoint | Subjective appetite (VAS for hunger, desire to eat, fullness, prospective food consumption) | X | X | X | X | X | X | X | X | ||
Behavioural endpoints | Food preference and reward (LFPQ) | X | X | ||||||||
Food cravings (CoEQ) | X | ||||||||||
Energy intake (24-hour dietary recall) | X | ||||||||||
Expected satiety | X (1 bite) | ||||||||||
Sensory-specific satiety | X (1 bite) | X | |||||||||
Other appetite ratings (eg, thirst, nausea, bloating, appetite for something sweet/savoury) | X | X | X | X | X | X | X | ||||
Metabolic endpoints | Glucose and insulin | X | X | X | X | X | X | ||||
Pancreatic polypeptide (PP)* | X | X | X | X | |||||||
GLP-1 and ghrelin | X | X | X | ||||||||
Lipaemia (triglycerides, total cholesterol, HDL-cholesterol and LDL-cholesterol) | X | X | X | X | |||||||
Health endpoints | Liver function (ALT, AST, GGT, FL index, TyG index) | X | X | ||||||||
HbA1c | CID1 and 6 | ||||||||||
24-hour GI side effects (self-report) | X |
*Time points for PP are earlier for yoghurt study.
ALT, alanine transaminase; AST, aspartate transaminase; CID, clinical investigation day; CoEQ, Control of Eating Questionnaire; FL index, fatty liver index; GGT, gamma-glutamyltransferase; GI, gastrointestinal; GLP-1, glucagon-like peptide 1; HbA1c, haemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LFPQ, Leeds Food Preference Questionnaire; TyG index, triglycerides and glucose index; VAS, Visual Analogue Scale.